DCGI's SEC to review applications of Bharat Biotech, SII for full market approval to Covaxin, Covishield today: Report

DCGI's SEC to review applications of Bharat Biotech, SII for full market approval to Covaxin, Covishield today: Report

ANIUpdated: Friday, January 14, 2022, 01:45 PM IST
article-image
Photo Credit: AFP

New Delhi: Drugs Controller General of India (DCGI)'s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said.

The SII of India had applied for market approval for the Covishield vaccine in December 2021 and Bharat biotech has also applied for the same 10 days ago.

Further, Bharat Biotech has informed that Covaxin is now a universal vaccine for adults and children. "Our goals of developing a global vaccine against COVID-19 have been achieved and all product development for licensure has been completed," it said.

However, both Covaxin and Covishield are currently authorized for emergency use only.

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) met on January 1 and January 2, 2021, and made recommendations in respect of the proposal for Restricted Emergency Approval of COVID-19 virus vaccines of Serum Institute of India and Bharat Biotech.

The SEC consists of domain knowledge experts from the fields of pulmonology, immunology, microbiology, pharmacology, pediatrics, internal medicine, etc.

It had reviewed the data on the safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in an emergency situation in the public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains. The clinical trial ongoing within the country by the firm will continue.

SII and Bharat Biotech vaccines have to be administered in two doses. All three vaccines have to be stored at 2-8 degrees Celsius.

After adequate examination, CDSCO had decided to accept the recommendations of the Expert Committee and accordingly, SII's Covishied and Bharat Biotech's Covaxin were approved for restricted use in an emergency situation.

Notably, the administration of Covaxin and Covishield began on January 16, 2021, in the country.

RECENT STORIES

INDIA Bloc Leaders To Join Mega Rally Organised By AAP Against Arvind Kejriwal's Arrest At Delhi's...

INDIA Bloc Leaders To Join Mega Rally Organised By AAP Against Arvind Kejriwal's Arrest At Delhi's...

UP: Govt Bus Driver, Conductor Assault Passenger, Bite Off His Ear & Finger After Argument Over...

UP: Govt Bus Driver, Conductor Assault Passenger, Bite Off His Ear & Finger After Argument Over...

'Can't Expect Any Better From Congress': Kangana Ranaut Hits Out At Party For Comments On 'Mandi's...

'Can't Expect Any Better From Congress': Kangana Ranaut Hits Out At Party For Comments On 'Mandi's...

Mukhtar Ansari Was Poisoned To Protect Another Mafia Don; Allege Family Members

Mukhtar Ansari Was Poisoned To Protect Another Mafia Don; Allege Family Members

Gujarat: Defence Secretary Giridhar Aramane Inaugurates Key Infrastructure At Indian Coast Guard...

Gujarat: Defence Secretary Giridhar Aramane Inaugurates Key Infrastructure At Indian Coast Guard...